FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  FRATTAROLI JOSEPH
 2. Date of Event Requiring Statement (Month/Day/Year)
12/22/2020		 3. Issuer Name and Ticker or Trading Symbol
Inhibikase Therapeutics, Inc. [IKT]
(Last)
(First)
(Middle)
3350 RIVERWOOD PARKWAY SE, SUITE 1900		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Financial Officer
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

ATLANTA, GA 30339		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant (right to buy) 08/25/2020 08/25/2027 Common Stock 21,854 $ 5.9 I By Flagship Consulting, Inc.
Warrant (right to buy) 08/25/2021 08/25/2027 Common Stock 150,000 $ 5.9 I By Flagship Consulting, Inc.
Convertible Note   (1) 12/31/2021 Common Stock (1) $ (1) I By Flagship Consulting, Inc.

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
FRATTAROLI JOSEPH
3350 RIVERWOOD PARKWAY SE, SUITE 1900
ATLANTA, GA 30339		       Chief Financial Officer  

Signatures

/s/ Milton H. Werner, attorney-in-fact 12/22/2020
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The Convertible Note has a maturity date of December 31, 2021. Prior to the maturity date, the Convertible Note will automatically convert into common stock of the Issuer if, on or prior to December 31, 2020, the Issuer consummates an initial public offering ("IPO") and will convert into such number of shares of common stock equal to the principal amount of the note, plus accrued and unpaid interest (which accrues at a rate of 5% per annum) as of the closing of the IPO, divided by the IPO price.
 
Remarks:
Exhibit List: Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.